Fei Liu

Fei Liu

Auto-generated profile, based on publicly available information

Fei Liu

Anhui Province Key Laboratory of Respiratory Tumor and Infectious Disease, the Department of Pulmonary Critical Care Medicine, First Affiliated Hospital of Bengbu Medical University, Bengbu, China

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2018 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
HZHaibo Zhou
Haibo Zhou
JLJunlai Liu
Junlai Liu
CZChangyang Zhou
Changyang Zhou
NGNi Gao
Ni Gao
ZRZhiping Rao
Zhiping Rao
HYHui Yang
Hui Yang

1 March 2022 in Cancer Research
Verified
Journal Article
Closed access
PDF file
XLXiaoyu Liu
Xiaoyu Liu
ZLZhi Li
Zhi Li
ZWZhongmin Wang
Zhongmin Wang
FLFei Liu
Fei Liu
LZLinling Zhang
Linling Zhang
XWXiaojing Wang
Xiaojing Wang
ARID1A is a key mammalian SWI/SNF complex subunit that is mutated in 5% to 11% of lung cancers. Although recent studies have elucidated the mechanism underlying dysregulation of the switch/sucrose non-fermentable (SWI/SNF) complexes in cancers, the significance of ARID1A loss and its implications in lung cancers remain poorly defined. This study investigates how ARID1A loss affects initiation and progression of lung cancer. In genetically engineered mouse models bearing mutant Kras and a deficient Trp53 allele (KP), ARID1A loss (KPA) promoted lung tumorigenesis. Analysis of the transcriptome profiles of KP and KPA tumors suggested enhanced glycolysis following ARID1A loss, and expression of the glycolytic regulators Pgam1, pyruvate kinase M (Pkm), and Pgk1 was significantly increased in ARID1A-deficient lung tumors. Furthermore, ARID1A loss increased chromatin accessibility and enhanced hypoxia-inducible factor-1α (HIF1α) binding to the promoter regions of Pgam1, Pkm, and Pgk1. Loss of ARID1A in lung adenocarcinoma also resulted in loss of histone deacetylase 1 (HDAC1) recruitment, increasing acetylation of histone-4 lysine at the promoters of Pgam1, Pkm, and Pgk1, and subsequently enhancing BRD4-driven transcription of these genes. Metabolic analyses confirmed that glycolysis is enhanced in ARID1A-deficient tumors, and genetic or pharmacologic inhibition of glycolysis inhibited lung tumorigenesis in KPA mice. Treatment with the small molecule bromodomain and extraterminal protein (BET) inhibitor JQ1 compromised both initiation and progression of ARID1A-deficient lung adenocarcinoma. ARID1A negatively correlated with glycolysis-related genes in human lung adenocarcinoma. Overall, ARID1A loss leads to metabolic reprogramming that supports tumorigenesis but also confers a therapeutic vulnerability that could be harnessed to improve the treatment of ARID1A-deficient lung cancer. Significance: This study links ARID1A loss with enhanced glycolysis in lung cancer and demonstrates the preclinical efficacy of BET inhibitor therapy as a strategy to combat tumor growth.

26 August 2014 in Science Signaling
Verified
Journal Article
Closed access
PDF file
KWKong-Yan Wu
Kong-Yan Wu
MHMiao He
Miao He
QHQiong-Qiong Hou
Qiong-Qiong Hou
ASAi-Li Sheng
Ai-Li Sheng
LYLei Yuan
Lei Yuan
ZLZhen-Ge Luo
Zhen-Ge Luo
Endocytosis contributes to axon collapse mediated by a repulsive guidance cue in the developing brain.

1 March 2021 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
FLFei Liu
Fei Liu
YZYijie Zhang
Yijie Zhang
FCFuliang Chen
Fuliang Chen
JYJiacheng Yuan
Jiacheng Yuan
SLSanlan Li
Sanlan Li
YLYueguang Liu
Yueguang Liu
Conversion of astrocytes into neurons in vivo offers an alternative therapeutic approach for neuronal loss after injury or disease. However, not only the efficiency of the conversion of astrocytes into functional neurons by single Neurog2, but also the conundrum that whether Neurog2-induced neuronal cells (Neurog2-iNs) are further functionally integrated into existing matured neural circuits remains unknown. Here, we adopted the AAV(2/8) delivery system to overexpress single factor Neurog2 into astrocytes and found that the majority of astrocytes were successfully converted into neuronal cells in multiple brain regions, including the midbrain and spinal cord. In the midbrain, Neurog2-induced neuronal cells (Neurog2-iNs) exhibit neuronal morphology, mature electrophysiological properties, glutamatergic identity (about 60%), and synapse-like configuration local circuits. In the spinal cord, astrocytes from both the intact and lesioned sources could be converted into functional neurons with ectopic expression of Neurog2 alone. Notably, further evidence from our study also proves that Neurog2-iNs in the intact spinal cord are capable of responding to diverse afferent inputs from dorsal root ganglion (DRG). Together, this study does not merely demonstrate the feasibility of Neurog2 for efficient in vivo reprogramming, it gives an indication for the Neurog2-iNs as a functional and potential factor in cell-replacement therapy.

1 December 2021 in Journal of Neurorestoratology
Verified
Journal Article
Open access
XGXiaoling Guo
Xiaoling Guo
YWYunliang Wang
Yunliang Wang
YLYan Li
Yan Li
YLYan-qiu Liu
Yan-qiu Liu
YLYing Liu
Ying Liu
HHHongyun Huang
Hongyun Huang

1 June 2019 in EBioMedicine
Verified
Journal Article
Open access
HGHuiyuan Gong
Huiyuan Gong
FLFei Liu
Fei Liu
XLXiaoyu Liu
Xiaoyu Liu
SMShengping Min
Shengping Min
NWNan Wu
Nan Wu
XWXiaojing Wang
Xiaojing Wang
The influence of amyloid protein-binding protein 2 (APPBP2) on lung cancer is unknown. The function and mechanisms of APPBP2 were investigated in the NSCLC cell lines A549 and H1299. The ectopic expression of APPBP2, PPM1D and SPOP in NSCLS were examined in samples collected from ten pairs of human lung adenocarcinoma cancer tissues and adjacent normal lung tissues. shRNA vector was used for APPBP2 knockdown. Quantitative PCR and western blot assays quantified the mRNA and protein level of APPBP2, PPM1D, and SPOP. Cell proliferation was measured with BrdU, MTT, colony formation assays, and xenograft tumour growth experiments. Cell migration and invasion were analysed with transwell and wound healing assays. Co-Immunoprecipitation assay detected protein-protein interactions. APPBP2 was upregulated in NSCLC tissues. Silencing APPBP2 in A549 and H1299 cells resulted in the inhibition of cell proliferation, migration, and invasion, enhancement of apoptosis, and a significant decrease in the expression of PPM1D and SPOP. Overexpression of PPM1D and SPOP attenuated the APPBP2-knockdown inhibition of NSCLC cells. Co-IP assay showed that PPM1D interacted with APPBP2. The expression level of APPBP2 positively correlates with NSCLC cell proliferation, migration, and invasiveness. APPBP2 contributes to NSCLC progression through regulating the PPM1D and SPOP signalling pathway. This novel molecular mechanism, underlying NSCLC oncogenesis, suggests APPBP2 is a potential target for diagnosis and therapeutic intervention in NSCLC. FUND: Key Program of Natural Science Research of Higher Education of Anhui Province (No. KJ2017A241), the National Natural Science Foundation of China (No. 81772493).